Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high114.00 02/06/17
52 week low10.50 08/01/18
52 week change -69.50 (-61.78%)
4 week volume182,330 27/04/18
price43.00
price date1527071243
close43.00

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
29/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
16/05/2014

Latest NewsMore

Holding(s) in Company

Notification of major interests in shares

Second Price Monitoring Extn

Price Monitoring Extension

Directorate Change

RNS Number: 1588M Akers Biosciences, Inc. 26 April 2018 April 26, 2018 Akers Biosciences, Inc. Directorate Change Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, on April 25, 2018, the board of directors (the "Board") of Akers Bio terminated Dr. Raymon...

Issue of Equity

RNS Number: 9409K Akers Biosciences, Inc. 13 April 2018 April 13, 2018 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that the Company has received further exercise notices from warrant holders to exercise warrants ov...

Independent Sales Representative Agreements - PIFA

RNS Number: 7092K Akers Biosciences, Inc. 12 April 2018 April 12, 2018 Akers Biosciences, Inc. Akers Bio Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (" Akers Bio " or the "Company"), a developer of rapid health information technologies, announces the engagement of two lead...

Issue of Equity

RNS Number: 1743K Akers Biosciences, Inc. 06 April 2018 April 6, 2018 Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that the Company has received further exercise notices from warrant holders to exercise warrants ove...

Final Results

RNS Number: 6126J Akers Biosciences, Inc. 03 April 2018 April 3, 2018 Akers Biosciences, Inc. Financial Results for the Year Ended December 31, 2017 Revenues Up 33% Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers", "Akers Bio" or the "Company"), a developer of rapid health information technologies, reports its financial results for the fiscal year ...

Latest discussion posts More

  • Re: BUY BUY BUY BUY BUY BUY

    Diagnostica Stago S.A.S (Stago), a privately held Company that provides reference tests and instrumentation in hemostasis, announced today that the company has entered a joint ...
    26-Mar-2018
    Gold or Silver
  • Re: BUY BUY BUY BUY BUY BUY

    Could it be that the news of approval has leaked ? Best of Luck All
    19-Mar-2018
    Gold or Silver
  • Re: BUY BUY BUY BUY BUY BUY

    Here we go. Best of Luck All
    27-Feb-2018
    Gold or Silver

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR